Information Provided By: 
Fly News Breaks for September 6, 2018
PFE, EXAS
Sep 6, 2018 | 08:41 EDT
BofA/Merrill analyst Derik de Bruin said Exact Sciences (EXAS) co-promotion agreement for Cologuard with Pfizer (PFE) adds significant "marketing muscle" to the company's strong fundamental story. The deal will help Exact Sciences penetrate healthcare systmes and allow the company to increase its advertising and promotional spect through better rates by utilizing Pfizer's purchasing power, the analyst wrote in a note to investors. de Bruin reiterates his Buy rating on Exact Sciences and increased his price target to $92 from $68 on shares.
News For EXAS;PFE From the Last 2 Days
PFE
Apr 25, 2024 | 10:25 EDT
Bullish option flow detected in Pfizer with 50,393 calls trading, 2x expected, and implied vol increasing over 2 points to 28.83%. Sep-24 27.5 calls and Mar-25 42.5 calls are the most active options, with total volume in those strikes near 27,600 contracts. The Put/Call Ratio is 0.21. Earnings are expected on May 1st.
